David Lau

1PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Feb 22, 2020
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.

David Lau, Eleftheria Kalaitzaki, David N Church

Pageof 1

Frequent Collaborators